share_log

SINOPHARM: Annual Report 2024

HKEX ·  Apr 25, 2025 16:30

Summary by Moomoo AI

國藥集團發佈2024年度業績報告，期內實現營業收入5,845.08億元人民幣，同比下降2.02%；淨利潤104.24億元，同比下降30.55%；股東應佔溢利70.50億元，同比下降22.14%。每股基本盈利2.26元人民幣，同比下降22.07%。董事會建議派發末期股息每股0.68元人民幣。從業務板塊來看，醫藥分銷業務收入4,443.65億元，同比增長0.75%；醫療器械分銷業務收入1,179.15億元，同比下降9.44%；零售藥房業務收入359.81億元，同比增長0.82%。公司資產負債率為67.75%，總資產達3,928.31億元。報告期內，公司未發生重大關聯交易，亦無向董事或相關實體提供貸款或準貸款。公司維持其作為非香港公司的註冊地位，並在中英文名稱下依據香港公司條例進行運營。
國藥集團發佈2024年度業績報告，期內實現營業收入5,845.08億元人民幣，同比下降2.02%；淨利潤104.24億元，同比下降30.55%；股東應佔溢利70.50億元，同比下降22.14%。每股基本盈利2.26元人民幣，同比下降22.07%。董事會建議派發末期股息每股0.68元人民幣。從業務板塊來看，醫藥分銷業務收入4,443.65億元，同比增長0.75%；醫療器械分銷業務收入1,179.15億元，同比下降9.44%；零售藥房業務收入359.81億元，同比增長0.82%。公司資產負債率為67.75%，總資產達3,928.31億元。報告期內，公司未發生重大關聯交易，亦無向董事或相關實體提供貸款或準貸款。公司維持其作為非香港公司的註冊地位，並在中英文名稱下依據香港公司條例進行運營。
China National Pharmaceutical Group released its annual performance report for 2024, achieving a revenue of 584.508 billion yuan, a year-on-year decrease of 2.02%; net profit of 10.424 billion yuan, a year-on-year decrease of 30.55%; and shareholders' profit attributable of 7.05 billion yuan, a year-on-year decrease of 22.14%. Basic earnings per share were 2.26 yuan, a year-on-year decrease of 22.07%. The Board of Directors recommended a final dividend of 0.68 yuan per share.From a Business Sector perspective, the revenue from pharmaceutical distribution was 444.365 billion yuan, a year-on-year increase of 0.75%; the revenue from medical instruments distribution was 117.915 billion yuan, a year-on-year decrease of 9.44%; and the revenue from retail pharmacy was 35.981 billion yuan, a year-on-year increase of 0.82%. The...Show More
China National Pharmaceutical Group released its annual performance report for 2024, achieving a revenue of 584.508 billion yuan, a year-on-year decrease of 2.02%; net profit of 10.424 billion yuan, a year-on-year decrease of 30.55%; and shareholders' profit attributable of 7.05 billion yuan, a year-on-year decrease of 22.14%. Basic earnings per share were 2.26 yuan, a year-on-year decrease of 22.07%. The Board of Directors recommended a final dividend of 0.68 yuan per share.From a Business Sector perspective, the revenue from pharmaceutical distribution was 444.365 billion yuan, a year-on-year increase of 0.75%; the revenue from medical instruments distribution was 117.915 billion yuan, a year-on-year decrease of 9.44%; and the revenue from retail pharmacy was 35.981 billion yuan, a year-on-year increase of 0.82%. The company's asset-liability ratio is 67.75%, with total assets reaching 392.831 billion yuan.During the reporting period, the company did not engage in any significant related transactions, nor did it provide loans or quasi-loans to directors or related entities. The company maintains its registered status as a non-Hong Kong company, operating in accordance with the Hong Kong Companies Ordinance under its Chinese and English names.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more